,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2017', 'fs': 'Feb 2017', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49A2AT'}, 'Id': 'a0POZ00000AB49A2AT', 'Event_Date__c': '2017-02-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2017', 'Status_History__c': 'a132P000000ArFBQA0'}, 'change': None}]",Feb 2017,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rheumatology-subcommittee-minutes-2017-10.pdf"" target=""_blank"">Rheumatology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rheumatology-subcommittee-minutes-2017-10.pdf"" target=""_blank"">Rheumatology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2017', 'fs': 'Oct 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rheumatology Subcommittee at meeting Tuesday 17 October 2017.', 'fs': 'Clinical advice received from Rheumatology Subcommittee at meeting Tuesday 17 October 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49B2AT'}, 'Id': 'a0POZ00000AB49B2AT', 'Event_Date__c': '2017-10-17', 'Event_Description__c': 'Clinical advice received from Rheumatology Subcommittee at meeting Tuesday 17 October 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-rheumatology-subcommittee-minutes-2017-10.pdf"" target=""_blank"">Rheumatology Subcommittee minutes</a>', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Oct 2017', 'Status_History__c': 'a132P000000ArLoQAK'}, 'change': None}, {'Summary': {'s': 'The Committee considered that tofacitinib was a new agent with many potential clinical uses and subsequent high fiscal risk. The Committee requested that the tofacitinib application be brought to PTAC for review.', 'fs': 'The Committee considered that tofacitinib was a new agent with many potential clinical uses and subsequent high fiscal risk. The Committee requested that the tofacitinib application be brought to PTAC for review.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49C2AT'}, 'Id': 'a0POZ00000AB49C2AT', 'Event_Date__c': '2018-02-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'The Committee considered that tofacitinib was a new agent with many potential clinical uses and subsequent high fiscal risk. The Committee requested that the tofacitinib application be brought to PTAC for review.', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArPAQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2019', 'fs': 'Aug 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49E2AT'}, 'Id': 'a0POZ00000AB49E2AT', 'Event_Date__c': '2019-08-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2019', 'Status_History__c': 'a132P000000ArhjQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended that tofacitinib be funded with a <b>medium</b> priority for patients with rheumatoid arthritis under the same Special Authority criteria in place for adalimumab and etanercept.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended that tofacitinib be funded with a <b>medium</b> priority for patients with moderate to severe rheumatoid arthritis who were not adequately responding to tumour necrosis factor inhibitors, subject to the Special Authority criteria recommended by the Rheumatology Subcommittee:</p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application – (rheumatoid arthritis)</b><span style=""font-size: 9pt;""> only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance. </span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Renewal</b><span style=""font-size: 9pt;""> </span><b style=""font-size: 9pt;"">– (rheumatoid arthritis)</b><span style=""font-size: 9pt;""> only from a rheumatologist or medical practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Both: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Following 3 to 4 months of initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.</span></p><p><br></p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended that tofacitinib be funded with a <b>medium</b> priority for patients with rheumatoid arthritis under the same Special Authority criteria in place for adalimumab and etanercept.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended that tofacitinib be funded with a <b>medium</b> priority for patients with moderate to severe rheumatoid arthritis who were not adequately responding to tumour necrosis factor inhibitors, subject to the Special Authority criteria recommended by the Rheumatology Subcommittee:</p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application – (rheumatoid arthritis)</b><span style=""font-size: 9pt;""> only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance. </span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Renewal</b><span style=""font-size: 9pt;""> </span><b style=""font-size: 9pt;"">– (rheumatoid arthritis)</b><span style=""font-size: 9pt;""> only from a rheumatologist or medical practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Both: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Following 3 to 4 months of initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.</span></p><p><br></p>', 'change': None}, 'Published_Discussion': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the application for tofacitinib was considered by the Rheumatology Subcommittee in <a href=""https://www.pharmac.govt.nz/assets/ptac-rheumatology-subcommittee-minutes-2017-10.pdf"" target=""_blank"">October 2017</a>. The Committee noted that in October 2017, the Rheumatology Subcommittee recommended that tofacitinib should be funded for patients with moderate to severe rheumatoid arthritis who were not adequately responding to TNF inhibitors with a high priority, and that tofacitinib should be funded for patients with rheumatoid arthritis under the same Special Authority criteria in place for adalimumab and etanercept with a medium priority.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that rheumatoid arthritis is a debilitating chronic inflammatory disease characterised by progressive, irreversible joint damage, impaired joint function, and pain. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that initial treatment options for rheumatoid arthritis include conventional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, hydroxychloroquine, ciclosporin, and leflunomide. The Committee noted that biologic DMARDs are initiated once a patient is not responding adequately to these agents.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the first-line biologic DMARDs are adalimumab and etanercept, which are tumour necrosis factor (TNF) inhibitors delivered by subcutaneous injection and funded in the community and hospitals. The Committee noted that second- and third-line biologic DMARDs include infliximab, rituximab, and tocilizumab, all of which are delivered via intravenous infusion and are only funded for use in hospitals.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee noted, without necessarily accepting, the supplier’s estimates that the prevalence of rheumatoid arthritis in New Zealand is approximately 3%, that approximately 20% of patients with rheumatoid arthritis are eligible for treatment with first-line biologic DMARDs, and that 30% of eligible patients are likely to receive treatment.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the application being considered requested funding for tofacitinib for patients who have had an inadequate response or are intolerant to methotrexate, which would position tofacitinib in the same line of therapy as adalimumab and etanercept.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tofacitinib is a selective inhibitor of the Janus kinase (JAK) family of enzymes, with primary activity against JAK1 and JAK3 and some activity against JAK2. The Committee noted that tofacitinib impairs the differentiation of CD4+ T helper cells, limits generation of pathogenic Th17 cells, blocks NK cell differentiation, and limits production of TNF and other proinflammatory cytokines. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tofacitinib 5 mg twice daily is approved by Medsafe for the treatment of signs and symptoms of moderate to severe active rheumatoid arthritis in adults who have an inadequate response or are intolerant to methotrexate. The Committee noted that tofacitinib is indicated for use alone or in combination with non-biologic DMARDs, including methotrexate.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted evidence provided by one Phase 2b and two Phase 3 trials that investigated the efficacy and safety of tofacitinib compared with placebo in patients with rheumatoid arthritis with an inadequate response to non-biologic DMARDs (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22006202"" target=""_blank"">Kremer et al. Arthritis Rheum. 2012;64:970-81</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/23348607"" target=""_blank"">van der Heijde et al. Arthritis Rheum. 2013;65:559-70</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/24026258"" target=""_blank"">Kremer et al. Ann Intern Med. 2013;159:253-61</a>). The Committee noted that these studies all reported that tofacitinib in combination with standard of care improved disease control compared with placebo and had a manageable safety profile.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a 24-week, double-blind, Phase 2b trial that investigated the efficacy and safety of tofacitinib (1, 3, 5, 10, 15 mg twice daily) or adalimumab (40\xa0mg subcutaneously every 2 weeks) monotherapy compared with placebo in 384 patients with rheumatoid arthritis with an inadequate response to non-biologic DMARDs (Trial 1035: <a href=""https://www.ncbi.nlm.nih.gov/pubmed/21952978"" target=""_blank"">Fleischmann et al. Arthritis Rheum. 2012;64:617-29</a>). The Committee noted that patients receiving adalimumab were switched to tofacitinib 5 mg at 12 weeks. The Committee noted that the proportion of patients achieving an ACR20 response at week 12 was 31.5% in the 1 mg arm (<i>P</i>=0.256), 39.2% in the 3 mg tofacitinib arm (P≤0.05), 59.2% in the 5\xa0mg arm (<i>P</i>&lt;0.0001), 70.5% in the 10 mg arm (<i>P</i>&lt;0.0001), 71.9% in the 15 mg arm (<i>P</i>&lt;0.0001), and 35.9% in the adalimumab arm (<i>P</i>=0.105), compared with 22.0% in the placebo arm. The Committee noted that the proportion of patients achieving an ACR20, ACR50, and ACR70 response at Week 24 was significantly higher in the tofacitinib 5 mg, 10 mg, and 15 mg arms compared with placebo. </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a 12-month, double-blind Phase 3 trial that investigated the efficacy and safety of tofacitinib (5 mg or 10 mg twice daily) or adalimumab (40\xa0mg subcutaneously every 2 weeks) compared with placebo in 717 patients with rheumatoid arthritis with an inadequate response to methotrexate (Trial 1064; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/22873531"" target=""_blank"">van Vollenhoven et al. N Engl J Med. 2012;367:508-19</a>). The Committee noted that all patients in this trial were receiving background methotrexate. The Committee considered that the most pertinent results were the ACR20 response rates at Month 6 without advancement penalty: 60.7% of patients receiving tofacitinib 5 mg, 62.8% of patients receiving tofacitinib 10 mg, and 58.3% of patients receiving adalimumab achieved an ACR20 response.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Health Assessment Questionnaire disability index (HAQ\xa0DI) results from Trial 1035 (Fleishmann et al. 2012) and Trial 1064 (van Vollenhoven et al. 2012). The Committee considered that the improvements in HAQ-DI scores observed in patients who received tofacitinib were equivalent to those seen in patients who received adalimumab. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of a meta-analysis provided by the supplier that included Trial 1035 and Trial 1064. The Committee considered that the results of this pooled analysis demonstrated that the ACR50 response rates for tofacitinib were higher than adalimumab, and the ACR20 and ACR70 response rates were not significantly different between the agents.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of an indirect comparison provided by the supplier that compared tofacitinib (8 studies) with adalimumab (8 studies). The Committee considered that the results of this analysis indicated that tofacitinib was non-inferior to adalimumab as monotherapy and combination therapy. The Committee noted the exception in the analysis was for ACR50 response at 3 months, which did not demonstrate non-inferiority of tofacitinib compared with adalimumab.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the safety findings of the indirect comparison provided by the supplier. The Committee considered that patients receiving tofacitinib had a slightly higher risk of gastrointestinal adverse events and infections and infestations compared with patients receiving adalimumab, but that the incidence of other adverse events was similar.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that there is limited data available to compare tofacitinib with etanercept. The Committee considered that there are no head-to-head trials, and that indirect comparisons have limited value as the etanercept trials were conducted more than a decade before the tofacitinib trials. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noting the above limitations, the Committee considered the indirect comparison of tofacitinib with etanercept provided by the supplier. The Committee considered that the results generally indicated that etanercept was superior to tofacitinib; however, members noted that the differences in patient population limited the value of this finding.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are concerns regarding the risk of herpes zoster infection (shingles) among patients receiving tofacitinib. The Committee noted that the incidence rates of herpes zoster infection in Trial 1035 and Trial 1064 were 2.8% among patients receiving tofacitinib and 1.9% among patients receiving adalimumab, and that these cases were all mild or moderate in severity. The Committee also noted the results of a review of 19 clinical studies which reported that the majority (~90%)\xa0of cases of herpes zoster infection among patients treated with tofacitinib were non-serious and involved only one dermatome (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28845604"" target=""_blank"">Winthrop et al. Arthritis Rheumatol. 2017;69:1960-1968</a>). Members considered that pre-treatment vaccination against herpes zoster with a non-live vaccine will be important if tofacitinib is funded.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there is an increased risk of cardiovascular disease among patients with rheumatoid arthritis. The Committee noted the results of a review of cardiovascular adverse events, blood pressure, and lipid level changes in patients receiving tofacitinib for rheumatoid arthritis, pooling data from six Phase 3 studies and two open-label long-term extension (LTE) studies (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27443588"" target=""_blank"">Charles-Schoeman et al. Semin Arthritis Rheum. 2016;46:261-71</a>). The Committee noted that this study concluded that tofacitinib was associated with an increase in lipid levels within the first three months of treatment, but that there was a low incidence of cardiovascular events (rate comparable to placebo).</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of serious adverse events occurring with ten biologic and targeted synthetic DMARDs for rheumatoid arthritis, including tofacitinib (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28013201"" target=""_blank"">Tarp et al. Rheumatology [Oxford]. 2017;56:417-25</a>). The Committee considered that this study broadly indicated that the incidence of serious adverse events was similar between agents except for certolizumab, which appeared to be associated with a higher incidence of serious adverse events compared with other agents.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the long-term safety of tofacitinib has been investigated in two extension studies: Trial 1041 and Trial 1029. The Committee noted a summary of the results provided by the supplier that indicated that the safety profile of tofacitinib long-term was consistent with the results observed in the Phase 2 and 3 trials. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the U.S. Food and Drug Administration has approved a warning of an increased risk of blood clots and death with tofacitinib 10 mg twice daily dosing. The Committee considered that this is likely to be of more concern for indications other than rheumatoid arthritis that require higher daily doses e.g. ulcerative colitis).</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if tofacitinib were to be funded, it is likely that clinicians would continue to prescribe adalimumab or etanercept as first-line biologic DMARDs for rheumatoid arthritis, due to their familiarity with these agents and the increased risk of herpes zoster infection associated with tofacitinib. The Committee considered that exceptions would be where an oral medication would be preferred over a subcutaneous injection.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence available adequately demonstrates that tofacitinib with or without methotrexate to be non-inferior to adalimumab for the treatment of rheumatoid arthritis, and that the safety profile of tofacitinib is manageable. </p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee accepted the Rheumatology Subcommittee’s consideration that the health need for an alternative treatment was greatest for patients who were not adequately responding to TNF inhibitors, but noted that there is limited evidence for this patient group. The Committee therefore considered it would be reasonable to recommend the use of tofacitinib in this population, but only with a medium priority.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the application for tofacitinib was considered by the Rheumatology Subcommittee in <a href=""https://www.pharmac.govt.nz/assets/ptac-rheumatology-subcommittee-minutes-2017-10.pdf"" target=""_blank"">October 2017</a>. The Committee noted that in October 2017, the Rheumatology Subcommittee recommended that tofacitinib should be funded for patients with moderate to severe rheumatoid arthritis who were not adequately responding to TNF inhibitors with a high priority, and that tofacitinib should be funded for patients with rheumatoid arthritis under the same Special Authority criteria in place for adalimumab and etanercept with a medium priority.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that rheumatoid arthritis is a debilitating chronic inflammatory disease characterised by progressive, irreversible joint damage, impaired joint function, and pain. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that initial treatment options for rheumatoid arthritis include conventional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, hydroxychloroquine, ciclosporin, and leflunomide. The Committee noted that biologic DMARDs are initiated once a patient is not responding adequately to these agents.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the first-line biologic DMARDs are adalimumab and etanercept, which are tumour necrosis factor (TNF) inhibitors delivered by subcutaneous injection and funded in the community and hospitals. The Committee noted that second- and third-line biologic DMARDs include infliximab, rituximab, and tocilizumab, all of which are delivered via intravenous infusion and are only funded for use in hospitals.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee noted, without necessarily accepting, the supplier’s estimates that the prevalence of rheumatoid arthritis in New Zealand is approximately 3%, that approximately 20% of patients with rheumatoid arthritis are eligible for treatment with first-line biologic DMARDs, and that 30% of eligible patients are likely to receive treatment.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the application being considered requested funding for tofacitinib for patients who have had an inadequate response or are intolerant to methotrexate, which would position tofacitinib in the same line of therapy as adalimumab and etanercept.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tofacitinib is a selective inhibitor of the Janus kinase (JAK) family of enzymes, with primary activity against JAK1 and JAK3 and some activity against JAK2. The Committee noted that tofacitinib impairs the differentiation of CD4+ T helper cells, limits generation of pathogenic Th17 cells, blocks NK cell differentiation, and limits production of TNF and other proinflammatory cytokines. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tofacitinib 5 mg twice daily is approved by Medsafe for the treatment of signs and symptoms of moderate to severe active rheumatoid arthritis in adults who have an inadequate response or are intolerant to methotrexate. The Committee noted that tofacitinib is indicated for use alone or in combination with non-biologic DMARDs, including methotrexate.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted evidence provided by one Phase 2b and two Phase 3 trials that investigated the efficacy and safety of tofacitinib compared with placebo in patients with rheumatoid arthritis with an inadequate response to non-biologic DMARDs (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22006202"" target=""_blank"">Kremer et al. Arthritis Rheum. 2012;64:970-81</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/23348607"" target=""_blank"">van der Heijde et al. Arthritis Rheum. 2013;65:559-70</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/24026258"" target=""_blank"">Kremer et al. Ann Intern Med. 2013;159:253-61</a>). The Committee noted that these studies all reported that tofacitinib in combination with standard of care improved disease control compared with placebo and had a manageable safety profile.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a 24-week, double-blind, Phase 2b trial that investigated the efficacy and safety of tofacitinib (1, 3, 5, 10, 15 mg twice daily) or adalimumab (40\xa0mg subcutaneously every 2 weeks) monotherapy compared with placebo in 384 patients with rheumatoid arthritis with an inadequate response to non-biologic DMARDs (Trial 1035: <a href=""https://www.ncbi.nlm.nih.gov/pubmed/21952978"" target=""_blank"">Fleischmann et al. Arthritis Rheum. 2012;64:617-29</a>). The Committee noted that patients receiving adalimumab were switched to tofacitinib 5 mg at 12 weeks. The Committee noted that the proportion of patients achieving an ACR20 response at week 12 was 31.5% in the 1 mg arm (<i>P</i>=0.256), 39.2% in the 3 mg tofacitinib arm (P≤0.05), 59.2% in the 5\xa0mg arm (<i>P</i>&lt;0.0001), 70.5% in the 10 mg arm (<i>P</i>&lt;0.0001), 71.9% in the 15 mg arm (<i>P</i>&lt;0.0001), and 35.9% in the adalimumab arm (<i>P</i>=0.105), compared with 22.0% in the placebo arm. The Committee noted that the proportion of patients achieving an ACR20, ACR50, and ACR70 response at Week 24 was significantly higher in the tofacitinib 5 mg, 10 mg, and 15 mg arms compared with placebo. </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a 12-month, double-blind Phase 3 trial that investigated the efficacy and safety of tofacitinib (5 mg or 10 mg twice daily) or adalimumab (40\xa0mg subcutaneously every 2 weeks) compared with placebo in 717 patients with rheumatoid arthritis with an inadequate response to methotrexate (Trial 1064; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/22873531"" target=""_blank"">van Vollenhoven et al. N Engl J Med. 2012;367:508-19</a>). The Committee noted that all patients in this trial were receiving background methotrexate. The Committee considered that the most pertinent results were the ACR20 response rates at Month 6 without advancement penalty: 60.7% of patients receiving tofacitinib 5 mg, 62.8% of patients receiving tofacitinib 10 mg, and 58.3% of patients receiving adalimumab achieved an ACR20 response.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Health Assessment Questionnaire disability index (HAQ\xa0DI) results from Trial 1035 (Fleishmann et al. 2012) and Trial 1064 (van Vollenhoven et al. 2012). The Committee considered that the improvements in HAQ-DI scores observed in patients who received tofacitinib were equivalent to those seen in patients who received adalimumab. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of a meta-analysis provided by the supplier that included Trial 1035 and Trial 1064. The Committee considered that the results of this pooled analysis demonstrated that the ACR50 response rates for tofacitinib were higher than adalimumab, and the ACR20 and ACR70 response rates were not significantly different between the agents.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of an indirect comparison provided by the supplier that compared tofacitinib (8 studies) with adalimumab (8 studies). The Committee considered that the results of this analysis indicated that tofacitinib was non-inferior to adalimumab as monotherapy and combination therapy. The Committee noted the exception in the analysis was for ACR50 response at 3 months, which did not demonstrate non-inferiority of tofacitinib compared with adalimumab.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the safety findings of the indirect comparison provided by the supplier. The Committee considered that patients receiving tofacitinib had a slightly higher risk of gastrointestinal adverse events and infections and infestations compared with patients receiving adalimumab, but that the incidence of other adverse events was similar.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that there is limited data available to compare tofacitinib with etanercept. The Committee considered that there are no head-to-head trials, and that indirect comparisons have limited value as the etanercept trials were conducted more than a decade before the tofacitinib trials. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noting the above limitations, the Committee considered the indirect comparison of tofacitinib with etanercept provided by the supplier. The Committee considered that the results generally indicated that etanercept was superior to tofacitinib; however, members noted that the differences in patient population limited the value of this finding.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are concerns regarding the risk of herpes zoster infection (shingles) among patients receiving tofacitinib. The Committee noted that the incidence rates of herpes zoster infection in Trial 1035 and Trial 1064 were 2.8% among patients receiving tofacitinib and 1.9% among patients receiving adalimumab, and that these cases were all mild or moderate in severity. The Committee also noted the results of a review of 19 clinical studies which reported that the majority (~90%)\xa0of cases of herpes zoster infection among patients treated with tofacitinib were non-serious and involved only one dermatome (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28845604"" target=""_blank"">Winthrop et al. Arthritis Rheumatol. 2017;69:1960-1968</a>). Members considered that pre-treatment vaccination against herpes zoster with a non-live vaccine will be important if tofacitinib is funded.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there is an increased risk of cardiovascular disease among patients with rheumatoid arthritis. The Committee noted the results of a review of cardiovascular adverse events, blood pressure, and lipid level changes in patients receiving tofacitinib for rheumatoid arthritis, pooling data from six Phase 3 studies and two open-label long-term extension (LTE) studies (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27443588"" target=""_blank"">Charles-Schoeman et al. Semin Arthritis Rheum. 2016;46:261-71</a>). The Committee noted that this study concluded that tofacitinib was associated with an increase in lipid levels within the first three months of treatment, but that there was a low incidence of cardiovascular events (rate comparable to placebo).</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of serious adverse events occurring with ten biologic and targeted synthetic DMARDs for rheumatoid arthritis, including tofacitinib (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28013201"" target=""_blank"">Tarp et al. Rheumatology [Oxford]. 2017;56:417-25</a>). The Committee considered that this study broadly indicated that the incidence of serious adverse events was similar between agents except for certolizumab, which appeared to be associated with a higher incidence of serious adverse events compared with other agents.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the long-term safety of tofacitinib has been investigated in two extension studies: Trial 1041 and Trial 1029. The Committee noted a summary of the results provided by the supplier that indicated that the safety profile of tofacitinib long-term was consistent with the results observed in the Phase 2 and 3 trials. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the U.S. Food and Drug Administration has approved a warning of an increased risk of blood clots and death with tofacitinib 10 mg twice daily dosing. The Committee considered that this is likely to be of more concern for indications other than rheumatoid arthritis that require higher daily doses e.g. ulcerative colitis).</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if tofacitinib were to be funded, it is likely that clinicians would continue to prescribe adalimumab or etanercept as first-line biologic DMARDs for rheumatoid arthritis, due to their familiarity with these agents and the increased risk of herpes zoster infection associated with tofacitinib. The Committee considered that exceptions would be where an oral medication would be preferred over a subcutaneous injection.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence available adequately demonstrates that tofacitinib with or without methotrexate to be non-inferior to adalimumab for the treatment of rheumatoid arthritis, and that the safety profile of tofacitinib is manageable. </p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee accepted the Rheumatology Subcommittee’s consideration that the health need for an alternative treatment was greatest for patients who were not adequately responding to TNF inhibitors, but noted that there is limited evidence for this patient group. The Committee therefore considered it would be reasonable to recommend the use of tofacitinib in this population, but only with a medium priority.</p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed an application for tofacitinib (Jaqinus) for the treatment of moderate to severe, active rheumatoid arthritis for patients who have had an inadequate response or are intolerant to methotrexate<span style=""color: gray;"">.</span> </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed an application for tofacitinib (Jaqinus) for the treatment of moderate to severe, active rheumatoid arthritis for patients who have had an inadequate response or are intolerant to methotrexate<span style=""color: gray;"">.</span> </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2019', 'fs': 'Nov 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 23 August 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 23 August 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49H2AT'}, 'Id': 'a0POZ00000AB49H2AT', 'Event_Date__c': '2019-11-22', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 23 August 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Nov 2019', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended that tofacitinib be funded with a <b>medium</b> priority for patients with rheumatoid arthritis under the same Special Authority criteria in place for adalimumab and etanercept.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended that tofacitinib be funded with a <b>medium</b> priority for patients with moderate to severe rheumatoid arthritis who were not adequately responding to tumour necrosis factor inhibitors, subject to the Special Authority criteria recommended by the Rheumatology Subcommittee:</p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application – (rheumatoid arthritis)</b><span style=""font-size: 9pt;""> only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance. </span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Renewal</b><span style=""font-size: 9pt;""> </span><b style=""font-size: 9pt;"">– (rheumatoid arthritis)</b><span style=""font-size: 9pt;""> only from a rheumatologist or medical practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Both: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Following 3 to 4 months of initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.</span></p><p><br></p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed an application for tofacitinib (Jaqinus) for the treatment of moderate to severe, active rheumatoid arthritis for patients who have had an inadequate response or are intolerant to methotrexate<span style=""color: gray;"">.</span> </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the application for tofacitinib was considered by the Rheumatology Subcommittee in <a href=""https://www.pharmac.govt.nz/assets/ptac-rheumatology-subcommittee-minutes-2017-10.pdf"" target=""_blank"">October 2017</a>. The Committee noted that in October 2017, the Rheumatology Subcommittee recommended that tofacitinib should be funded for patients with moderate to severe rheumatoid arthritis who were not adequately responding to TNF inhibitors with a high priority, and that tofacitinib should be funded for patients with rheumatoid arthritis under the same Special Authority criteria in place for adalimumab and etanercept with a medium priority.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that rheumatoid arthritis is a debilitating chronic inflammatory disease characterised by progressive, irreversible joint damage, impaired joint function, and pain. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that initial treatment options for rheumatoid arthritis include conventional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, hydroxychloroquine, ciclosporin, and leflunomide. The Committee noted that biologic DMARDs are initiated once a patient is not responding adequately to these agents.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the first-line biologic DMARDs are adalimumab and etanercept, which are tumour necrosis factor (TNF) inhibitors delivered by subcutaneous injection and funded in the community and hospitals. The Committee noted that second- and third-line biologic DMARDs include infliximab, rituximab, and tocilizumab, all of which are delivered via intravenous infusion and are only funded for use in hospitals.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>\xa0The Committee noted, without necessarily accepting, the supplier’s estimates that the prevalence of rheumatoid arthritis in New Zealand is approximately 3%, that approximately 20% of patients with rheumatoid arthritis are eligible for treatment with first-line biologic DMARDs, and that 30% of eligible patients are likely to receive treatment.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the application being considered requested funding for tofacitinib for patients who have had an inadequate response or are intolerant to methotrexate, which would position tofacitinib in the same line of therapy as adalimumab and etanercept.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tofacitinib is a selective inhibitor of the Janus kinase (JAK) family of enzymes, with primary activity against JAK1 and JAK3 and some activity against JAK2. The Committee noted that tofacitinib impairs the differentiation of CD4+ T helper cells, limits generation of pathogenic Th17 cells, blocks NK cell differentiation, and limits production of TNF and other proinflammatory cytokines. </p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tofacitinib 5 mg twice daily is approved by Medsafe for the treatment of signs and symptoms of moderate to severe active rheumatoid arthritis in adults who have an inadequate response or are intolerant to methotrexate. The Committee noted that tofacitinib is indicated for use alone or in combination with non-biologic DMARDs, including methotrexate.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted evidence provided by one Phase 2b and two Phase 3 trials that investigated the efficacy and safety of tofacitinib compared with placebo in patients with rheumatoid arthritis with an inadequate response to non-biologic DMARDs (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22006202"" target=""_blank"">Kremer et al. Arthritis Rheum. 2012;64:970-81</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/23348607"" target=""_blank"">van der Heijde et al. Arthritis Rheum. 2013;65:559-70</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/24026258"" target=""_blank"">Kremer et al. Ann Intern Med. 2013;159:253-61</a>). The Committee noted that these studies all reported that tofacitinib in combination with standard of care improved disease control compared with placebo and had a manageable safety profile.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a 24-week, double-blind, Phase 2b trial that investigated the efficacy and safety of tofacitinib (1, 3, 5, 10, 15 mg twice daily) or adalimumab (40\xa0mg subcutaneously every 2 weeks) monotherapy compared with placebo in 384 patients with rheumatoid arthritis with an inadequate response to non-biologic DMARDs (Trial 1035: <a href=""https://www.ncbi.nlm.nih.gov/pubmed/21952978"" target=""_blank"">Fleischmann et al. Arthritis Rheum. 2012;64:617-29</a>). The Committee noted that patients receiving adalimumab were switched to tofacitinib 5 mg at 12 weeks. The Committee noted that the proportion of patients achieving an ACR20 response at week 12 was 31.5% in the 1 mg arm (<i>P</i>=0.256), 39.2% in the 3 mg tofacitinib arm (P≤0.05), 59.2% in the 5\xa0mg arm (<i>P</i>&lt;0.0001), 70.5% in the 10 mg arm (<i>P</i>&lt;0.0001), 71.9% in the 15 mg arm (<i>P</i>&lt;0.0001), and 35.9% in the adalimumab arm (<i>P</i>=0.105), compared with 22.0% in the placebo arm. The Committee noted that the proportion of patients achieving an ACR20, ACR50, and ACR70 response at Week 24 was significantly higher in the tofacitinib 5 mg, 10 mg, and 15 mg arms compared with placebo. </p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a 12-month, double-blind Phase 3 trial that investigated the efficacy and safety of tofacitinib (5 mg or 10 mg twice daily) or adalimumab (40\xa0mg subcutaneously every 2 weeks) compared with placebo in 717 patients with rheumatoid arthritis with an inadequate response to methotrexate (Trial 1064; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/22873531"" target=""_blank"">van Vollenhoven et al. N Engl J Med. 2012;367:508-19</a>). The Committee noted that all patients in this trial were receiving background methotrexate. The Committee considered that the most pertinent results were the ACR20 response rates at Month 6 without advancement penalty: 60.7% of patients receiving tofacitinib 5 mg, 62.8% of patients receiving tofacitinib 10 mg, and 58.3% of patients receiving adalimumab achieved an ACR20 response.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Health Assessment Questionnaire disability index (HAQ\xa0DI) results from Trial 1035 (Fleishmann et al. 2012) and Trial 1064 (van Vollenhoven et al. 2012). The Committee considered that the improvements in HAQ-DI scores observed in patients who received tofacitinib were equivalent to those seen in patients who received adalimumab. </p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of a meta-analysis provided by the supplier that included Trial 1035 and Trial 1064. The Committee considered that the results of this pooled analysis demonstrated that the ACR50 response rates for tofacitinib were higher than adalimumab, and the ACR20 and ACR70 response rates were not significantly different between the agents.</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of an indirect comparison provided by the supplier that compared tofacitinib (8 studies) with adalimumab (8 studies). The Committee considered that the results of this analysis indicated that tofacitinib was non-inferior to adalimumab as monotherapy and combination therapy. The Committee noted the exception in the analysis was for ACR50 response at 3 months, which did not demonstrate non-inferiority of tofacitinib compared with adalimumab.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the safety findings of the indirect comparison provided by the supplier. The Committee considered that patients receiving tofacitinib had a slightly higher risk of gastrointestinal adverse events and infections and infestations compared with patients receiving adalimumab, but that the incidence of other adverse events was similar.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that there is limited data available to compare tofacitinib with etanercept. The Committee considered that there are no head-to-head trials, and that indirect comparisons have limited value as the etanercept trials were conducted more than a decade before the tofacitinib trials. </p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Noting the above limitations, the Committee considered the indirect comparison of tofacitinib with etanercept provided by the supplier. The Committee considered that the results generally indicated that etanercept was superior to tofacitinib; however, members noted that the differences in patient population limited the value of this finding.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are concerns regarding the risk of herpes zoster infection (shingles) among patients receiving tofacitinib. The Committee noted that the incidence rates of herpes zoster infection in Trial 1035 and Trial 1064 were 2.8% among patients receiving tofacitinib and 1.9% among patients receiving adalimumab, and that these cases were all mild or moderate in severity. The Committee also noted the results of a review of 19 clinical studies which reported that the majority (~90%)\xa0of cases of herpes zoster infection among patients treated with tofacitinib were non-serious and involved only one dermatome (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28845604"" target=""_blank"">Winthrop et al. Arthritis Rheumatol. 2017;69:1960-1968</a>). Members considered that pre-treatment vaccination against herpes zoster with a non-live vaccine will be important if tofacitinib is funded.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there is an increased risk of cardiovascular disease among patients with rheumatoid arthritis. The Committee noted the results of a review of cardiovascular adverse events, blood pressure, and lipid level changes in patients receiving tofacitinib for rheumatoid arthritis, pooling data from six Phase 3 studies and two open-label long-term extension (LTE) studies (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27443588"" target=""_blank"">Charles-Schoeman et al. Semin Arthritis Rheum. 2016;46:261-71</a>). The Committee noted that this study concluded that tofacitinib was associated with an increase in lipid levels within the first three months of treatment, but that there was a low incidence of cardiovascular events (rate comparable to placebo).</p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted a systematic review of serious adverse events occurring with ten biologic and targeted synthetic DMARDs for rheumatoid arthritis, including tofacitinib (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28013201"" target=""_blank"">Tarp et al. Rheumatology [Oxford]. 2017;56:417-25</a>). The Committee considered that this study broadly indicated that the incidence of serious adverse events was similar between agents except for certolizumab, which appeared to be associated with a higher incidence of serious adverse events compared with other agents.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the long-term safety of tofacitinib has been investigated in two extension studies: Trial 1041 and Trial 1029. The Committee noted a summary of the results provided by the supplier that indicated that the safety profile of tofacitinib long-term was consistent with the results observed in the Phase 2 and 3 trials. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the U.S. Food and Drug Administration has approved a warning of an increased risk of blood clots and death with tofacitinib 10 mg twice daily dosing. The Committee considered that this is likely to be of more concern for indications other than rheumatoid arthritis that require higher daily doses e.g. ulcerative colitis).</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that if tofacitinib were to be funded, it is likely that clinicians would continue to prescribe adalimumab or etanercept as first-line biologic DMARDs for rheumatoid arthritis, due to their familiarity with these agents and the increased risk of herpes zoster infection associated with tofacitinib. The Committee considered that exceptions would be where an oral medication would be preferred over a subcutaneous injection.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the evidence available adequately demonstrates that tofacitinib with or without methotrexate to be non-inferior to adalimumab for the treatment of rheumatoid arthritis, and that the safety profile of tofacitinib is manageable. </p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee accepted the Rheumatology Subcommittee’s consideration that the health need for an alternative treatment was greatest for patients who were not adequately responding to TNF inhibitors, but noted that there is limited evidence for this patient group. The Committee therefore considered it would be reasonable to recommend the use of tofacitinib in this population, but only with a medium priority.</p>', 'Status_History__c': 'a132P000000BAYoQAO'}, 'change': None}]",Oct 2017,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2020', 'fs': 'Jan 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49I2AT'}, 'Id': 'a0POZ00000AB49I2AT', 'Event_Date__c': '2020-01-13', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jan 2020', 'Status_History__c': 'a132P000000BNcxQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2024', 'fs': 'Jul 2024', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49K2AT'}, 'Id': 'a0POZ00000AB49K2AT', 'Event_Date__c': '2024-07-04', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jul 2024', 'Status_History__c': 'a13OZ00000BpFWXYA3'}, 'change': None}]",Jan 2020,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49D2AT'}, 'Id': 'a0POZ00000AB49D2AT', 'Event_Date__c': '2018-09-04', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArWYQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2019', 'fs': 'Sep 2019', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49F2AT'}, 'Id': 'a0POZ00000AB49F2AT', 'Event_Date__c': '2019-09-12', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2019', 'Status_History__c': 'a132P000000AuzmQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2019', 'fs': 'Nov 2019', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49G2AT'}, 'Id': 'a0POZ00000AB49G2AT', 'Event_Date__c': '2019-11-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2019', 'Status_History__c': 'a132P000000B7sDQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2021', 'fs': 'Feb 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000AB49J2AT'}, 'Id': 'a0POZ00000AB49J2AT', 'Event_Date__c': '2021-02-25', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Feb 2021', 'Status_History__c': 'a132P000000CdNOQA0'}, 'change': None}]",Sep 2018,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
